Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older

• Váldodahkkit: Makoto Shiragami (Dahkki), Akiko Mizukami (Dahkki), Toshihiko Kaise (Dahkki), Desmond Curran (Dahkki), Desiree Van Oorschot (Dahkki), Benjamin Bracke (Dahkki), Daisuke Watanabe (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Adis, Springer Healthcare, 2019-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Introduction The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiv...